Key result
Preoperative levosimendan improved hemodynamics and significantly reduced the need for ventilatory support, intensive care unit stay, and hospital stay compared to placebo (all p < 0.0001).
Why the study?
Does preoperative levosimendan improve hemodynamics and clinical outcomes in patients with LVEF <30% undergoing CABG and mitral valve repair?
RCT (n=40)
Double-blind
Does preoperative levosimendan improve hemodynamics and clinical outcomes in patients with LVEF <30% undergoing CABG and mitral valve repair?
p-value: p=<0.0001
Preoperative administration of levosimendan improves hemodynamics and significantly reduces ICU and hospital length of stay in patients with severe left ventricular dysfunction undergoing CABG and mitral valve repair.
No takes yet. Share an insight, caveat, or question.
Supports preoperative levosimendan in LVEF <30% CABG and mitral repair; extends perioperative inotrope evidence to this high-risk group.
Sharma et al. (2013) conducted an RCT in Ischemic mitral valve disease with low left ventricular ejection fraction (n=40). Levosimendan vs. Placebo was evaluated on Hemodynamic effects (cardiac index and mean arterial pressure) (p=<0.0001). Preoperative levosimendan improved hemodynamics and significantly reduced the need for ventilatory support, intensive care unit stay, and hospital stay compared to placebo (all p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: